AG-636 is a potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 17 nM. Differential AG-636 activity translated to the in vivo setting, with complete tumor regression observed in a lymphoma model. Dissection of the relationship between uridine availability and response to AG-636 revealed a divergent ability of lymphoma and solid tumor cell lines to survive and grow in the setting of depleted extracellular uridine and DHODH inhibition. Metabolic characterization paired with unbiased functional genomic and proteomic screens pointed to adaptive mechanisms to cope with nucleotide stress as contributing to response to AG-636.
Properties:
Boiling point: 619.3±43.0 °C(Predicted)
density: 1.27±0.1 g/cm3(Predicted)
pka: 2.73±0.10(Predicted)
Dehydrogenase Inhibitors Related Products:
Mycophenolate mofetil; AGI-5198; SW033291; Vidofludimus; AGI-6780; Devimistat (CPI-613); Mycophenolic acid; Trilostane; Tenovin-1; Teriflunomide; Gimeracil; AG-120 (racemic); Ivosidenib; Brequinar